Patents by Inventor Michael P. Arend

Michael P. Arend has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
    Patent number: 9643928
    Abstract: The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), the process of preparing crystalline forms of Compound A, the pharmaceutical compositions containing them, and the methods of use thereof.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: May 9, 2017
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Michael D. Thompson, Jung Min Park, Michael P. Arend
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 9617218
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: April 11, 2017
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170035747
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: April 19, 2016
    Publication date: February 9, 2017
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20160331741
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: May 18, 2016
    Publication date: November 17, 2016
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
    Patent number: 9409892
    Abstract: The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: August 9, 2016
    Assignee: FibroGen, Inc.
    Inventors: Wen-Bin Ho, Hongda Zhao, Shaojiang Deng, Danny Ng, Lee R. Wright, Min Wu, Xiaoti Zhou, Michael P. Arend, Lee A. Flippin
  • Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
    Patent number: 9387200
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: July 12, 2016
    Assignee: FibroGen, Inc.
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS
    Publication number: 20160194285
    Abstract: The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: March 17, 2016
    Publication date: July 7, 2016
    Inventors: Michael D. Thompson, Jung Min Park, Michael P. Arend
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 9371288
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: June 21, 2016
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20160159796
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • Process for making isoquinoline compounds
    Patent number: 9340511
    Abstract: The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 17, 2016
    Assignee: FibroGen, Inc.
    Inventors: Michael D. Thompson, Jung Min Park, Michael P. Arend
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 9339527
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 17, 2016
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
    Patent number: 9271970
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 1, 2016
    Assignee: FIBROGEN, INC.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • CRYSTALLINE FORMS OF -ACETIC ACID
    Publication number: 20160002170
    Abstract: The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), the process of preparing crystalline forms of Compound A, the pharmaceutical compositions containing them, and the methods of use thereof.
    Type: Application
    Filed: January 23, 2014
    Publication date: January 7, 2016
    Inventors: Claudia WITSCHI, Michael D. THOMPSON, Jung Min PARK, Michael P. AREND
  • CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
    Publication number: 20150322015
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 21, 2015
    Publication date: November 12, 2015
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Crystalline forms of a prolyl hydroxylase inhibitor
    Patent number: 9115085
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: August 25, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY
    Publication number: 20150209336
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20150174110
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: December 23, 2014
    Publication date: June 25, 2015
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS
    Publication number: 20150175550
    Abstract: The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: July 15, 2013
    Publication date: June 25, 2015
    Inventors: Michael D. Thompson, Jung Min Park, Michael P. Arend
  • Thienopyridine compounds, and methods of use thereof
    Patent number: 9000006
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: April 7, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20150080425
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 19, 2015
    Applicant: FibroGen, Inc.
    Inventors: STEPHEN J. KLAUS, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov